# US 2024/0189241 A1 · Phospholipids as anion chelating agents in pharmaceutical formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189241 A1
- Document ID: US20240189241A1
- Status: Published application
- Kind: A1
- Application number: 18/284,916
- Filed: 2022-03-31
- Published: 2024-06-13
- Earliest claimed: 2021-04-01
- Assignees: R.P. Scherer Technologies, LLC
- Applicants: R.P. Scherer Technologies, LLC
- Inventors: Giang Hoang Thuy Au; William Derek Bush
- Web page: https://patentgrep.com/patent/US20240189241A1

## CPC

- A61K 9/4858: {Organic compounds}
- A61J 3/07: into the form of capsules or similar small containers for oral use
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/485: {Inorganic compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE

## Abstract

Disclosed herein are dosage forms including a fill material that incorporates an anionic chelating agent, such as lecithin, and a salt form of a basic or acidic active pharmaceutical ingredient and a free ion. The molar ratio of the anionic chelating agent, such as lecithin, to the free ion ranging from about 0.5 to about 3. Also disclosed herein are methods of stabilizing dosage forms that include a salt form of a basic or acidic active pharmaceutical ingredient, methods of preparing such dosage forms, and methods of using such dosage forms.

## Claims

### Claim 1

A capsule comprising:
a fill material,
wherein the fill material comprises:
a salt form of a basic or acidic active pharmaceutical ingredient (API) and a free anion,
an anionic chelating agent comprising lecithin,
wherein the molar ratio of the anionic chelating agent to the free anion ranges from about 0.5 to about 3; and
a shell composition.

### Claim 2 (depends on 1)

The capsule of claim 1, wherein the capsule maintains its integrity at 40° C., and 3 weeks of storage, wherein the integrity of the capsule is measured based on leakage of the fill material from the shell composition.

### Claim 3 (depends on 2)

The capsule of claim 2, wherein the free anion is chloride, bromide, fluoride, sulfate, phosphate, formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, nitrate, or a combination thereof.

### Claim 4 (depends on 1)

The capsule of claim 1, wherein the fill material comprises from about 0.1 wt % to about 50 wt % API, based on total weight of the fill material.

### Claim 5 (depends on 1)

The capsule of claim 1, wherein the fill material comprises from about 1 wt % to about 50 wt % anionic chelating agent, based on total weight of the fill material.

### Claim 6 (depends on 1)

The capsule of claim 1, wherein the molar ratio of anionic chelating agent to the free anion range from about 0.8 to about 2.8.

### Claim 7 (depends on 1)

The capsule of claim 1, wherein the lecithin comprises from about 10 wt % to about 95 wt % phospholipid components with positively charged functional groups, based on total weight of the lecithin.

### Claim 8 (depends on 1)

The capsule of claim 1, wherein the lecithin comprises from about 10 wt % to about 95 wt % phosphatides comprising one or more of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS).

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The capsule of claim 1, wherein the fill material further comprises a lipid-based matrix comprising one or more of glycerides, triglycerides, semi-synthetic ester glycerides, fatty acids, alcohols, fatty acid esters, lipophilic surfactants, hydrophilic surfactants, carbohydrates, and co-solvents, and combinations thereof.

### Claim 12 (depends on 11)

The capsule of claim 11, wherein the lipid-based matrix comprises vegetable oils.

### Claim at position 13

-15. (canceled)

### Claim 16 (depends on 11)

The capsule of claim 11, wherein the lipid-based matrix comprises fatty acids with the formulation R—C(═)—OH, wherein R is C4-C20, and wherein the fatty acids are fully saturated or contain one or more sites of unsaturation.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 11)

The capsule of claim 11, wherein the lipid-based matrix comprises one or more alcohols, fatty acid esters, and a combination thereof.

### Claim 20 (depends on 19)

The capsule of claim 19, wherein the alcohols comprise one or more of ethanol, isopropanol, isobutanol, glycerol, propylene glycol.

### Claim 21

(canceled)

### Claim 22 (depends on 19)

The capsule of claim 19, wherein the fatty acid esters comprise mono-,di-, tri-esters of medium chain or long-chain fatty acid surfactants and/or co-solvents.

### Claim 23 (depends on 11)

The capsule of claim 11, wherein the surfactants and/or co-solvents comprise polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyethylene glycol, polysorbate 80, span 80, labrafil M2125, labrasol, gelucire 44/14, and combinations thereof.

### Claim 24 (depends on 1)

The capsule of claim 1, wherein the capsule is a softgel capsule.

### Claim at position 23

-27. (canceled)

### Claim 28 (depends on 1)

A process of preparing a capsule of claim 1, the process comprising:
preparing the fill material; and
encapsulating the fill material with the shell composition.

### Claim 29

A process of stabilizing a capsule comprising:
combining a salt form of a basic or acidic active pharmaceutical ingredient (API) and a free anion with an anionic chelating agent comprising lecithin at a molar ratio of anionic chelating agent to free anion of about 0.5 to about 3 to prepare a fill material; and
encapsulating the fill material in a shell composition.

### Claim 30 (depends on 29)

The process of claim 29, wherein the capsule maintains its integrity at 40° C., and 3 weeks of storage, wherein the integrity of the capsule is measured based on leakage of the fill material from the shell composition.

### Claim 31

A capsule comprising:
a fill material,
wherein the fill material comprises:
a salt form of a basic or acidic active pharmaceutical ingredient (API) and a free anion,
an anionic chelating agent comprising lecithin, wherein the lecithin comprises from about 10 wt % to about 95 wt % phospholipid components with positively charged functional groups, based on total weight of the lecithin; and
a shell composition,
wherein the capsule maintains its integrity at 40° C., and 3 weeks of storage, wherein the integrity of the capsule is measured based on leakage of the fill material from the shell composition.
